Literature DB >> 8848182

Prevalence of Parkinson's disease in the elderly: the Rotterdam Study.

M C de Rijk1, M M Breteler, G A Graveland, A Ott, D E Grobbee, F G van der Meché, A Hofman.   

Abstract

We assessed the prevalence of Parkinson's disease (PD) in a general elderly population in the Netherlands. The study formed part of the Rotterdam Study, a population-based door-to-door study, and included 6,969 persons 55 years of age or older living in a suburb of Rotterdam, the Netherlands. All participants were examined, and those who either had at least one possible cardinal sign of parkinsonism at the neurologic screening, reported that they had PD, or were taking antiparkinsonian drugs were invited for further evaluation. The prevalence of PD in this population was 1.4% (1.2% for men, 1.5% for women). Prevalence increased with age, and prevalence figures were 0.3% for those aged 55 to 64 years, 1.0% for those 65 to 74, 3.1% for those 75 to 84, and 4.3% for those 85 to 94. The corresponding age-specific figures for men were 0.4%, 1.2%, 2.7%, and 3.0%, and for women, 0.2%, 0.8%, 3.4%, and 4.8%. Among 95- to 99-year-old women the prevalence was 5.0%. Twelve percent of the subjects with PD were detected through the screening and had not been diagnosed previously.

Entities:  

Mesh:

Year:  1995        PMID: 8848182     DOI: 10.1212/wnl.45.12.2143

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  119 in total

Review 1.  Bromocriptine for levodopa-induced motor complications in Parkinson's disease.

Authors:  J J van Hilten; C Ramaker; W J Van de Beek; M J Finken
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

3.  Determinants of locomotor disability in people aged 55 years and over: the Rotterdam Study.

Authors:  E Odding; H A Valkenburg; H J Stam; A Hofman
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 4.  Screening questionnaires for parkinsonism: a systematic review.

Authors:  Nabila Dahodwala; Andrew Siderowf; Mona Baumgarten; Aaron Abrams; Jason Karlawish
Journal:  Parkinsonism Relat Disord       Date:  2011-09-17       Impact factor: 4.891

5.  How valid is the clinical diagnosis of Parkinson's disease in the community?

Authors:  A Schrag; Y Ben-Shlomo; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

Review 6.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 7.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

8.  Clinical expression of LRRK2 G2019S mutations in the elderly.

Authors:  Marta San Luciano; Richard B Lipton; Cuiling Wang; Mindy Katz; Molly E Zimmerman; Amy E Sanders; Laurie J Ozelius; Susan B Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

9.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

10.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.